Because of the good results achieved with
tamoxifen in the treatment of
oligozoospermia and with
kallikrein in the treatment of
asthenozoospermia, a randomized study of the combined treatment of oligoasthenozoospermia suggested itself. 67 patients with idiopathic normogonadotropic oligoasthenozoospermia were treated with 30 mg
tamoxifen/day (n = 33) or with 30 mg
tamoxifen/day and additionally 600 IU
kallikrein/day (n = 34). It was shown that, apart from a significant increase in sperm density in both groups, the combination
therapy also resulted in an overall significant increase (p less than 0.02) in sperm motility. Sperm morphology and the swell test remained unaffected. After 3 months of
therapy, 4 pregnancies occurred in each group. In ejaculates with a sperm density of less than 10 million/ml not even one sperm parameter was significantly affected in any of the groups, while with an initial value of more than 10 million/ml the increase in motility was more significant (p less than 0.008) in the group with additional
kallikrein therapy (n = 18). In the monotherapy group, no significant
therapeutic effect on sperm motility was seen even in patients with a sperm density of more than 10 million. The combination of
tamoxifen and
kallikrein therefore seems to constitute an improvement of the systemic
therapy of
male subfertility in patients with moderately severe oligoasthenozoospermia.